Related Experiment Video
Updated: Jan 12, 2026

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
Multi criterion decision making analysis of hematologic cancer drugs via topological indices and physicochemical
Lina Huang1,2, Saba Hanif3, Muhammad Kamran Siddiqui3
1Department of Rehabilitation, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Abstract:
In this research, quantitative structure property relationship (QSPR) regression along with multi criteria decision making (MCDM) approaches, including TOPSIS and Simple Additive Weighting (SAW), is deployed to rank the antihematological cancer drugs by structural and physicochemical attributes. Topological indices like zagreb, Randic and Atom Bond Connectivity (ABC) indices are calculated with the Maple program and chemspider was employed to obtain physicochemical descriptors such as boiling point; molar refraction; polarizability and molar volume which are both modeled using cubic and logarithm regression. The cubic model performed better than the logarithmic models, both in terms of correlation coefficients and predictive accuracy. In the present study, two compounds with more complexity of structure and greater connectivity, Carfilzomib and Zanubrutinib were ranked higher by QSPR and MCDM model considering the structural features compared to those with simpler molecular frameworks including Cyclophosphamide and Cytarabine which was placed lower. The above results suggest that compositing QSPR regression and MCDM is applicable towards computationally automatic, yet efficient process for screening drug candidates systematically at the beginning stages of hematologic cancer therapies.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018